RNS Number:1246I
EpiStem Holdings plc
20 November 2007
For release: 20th November 2007
                              Placing Announcement
Epistem Holdings Plc (the "Company"), the biotechnology company which
commercialises adult stem cells in the areas of oncology and gastrointestinal
diseases, announced today that it has raised #1,065,703.78 by a placing of
653,806 Ordinary Shares of #0.015 each at an issue price of #1.63 per share, the
mid market price at the time the placing was agreed.
The Company will use the proceeds of this placing to accelerate the development
of its high sensitivity gene expression biomarker technology. The biomarker
platform analyses changes in gene expression from RNA extracted from cells
located at the base of a single human plucked hair. Epistem has developed the
biomarker platform to identify drug-induced changes in gene expression for
application in preclinical and clinical drug development.
The shares issued pursuant to the Placing were placed on 15th November 2007 with
the following existing shareholders of the Company:
306,903 Ordinary Shares with Calculus Capital Limited;
306,903 Ordinary Shares with Helium Special Situations Fund; and
40,000 Ordinary Shares with New Star Asset Management.
The Company confirms that it has sufficient authorised but unissued share
capital to effect the Placing and that the directors have been granted the
necessary authority by the shareholders under section 80 of the Companies Act
1985 and that the statutory pre-emption rights under section 89 of the Companies
Act 1985 have been disapplied in relation to the Placing Shares.  The Placing
Shares will rank pari passu with the existing ordinary shares of #0.015 in the
capital of the Company.  The Placing has been arranged by Landsbanki Securities
(UK) Limited.
As a result of the Placing, the issued share capital of the Company will
increase to 7,191,883 Ordinary Shares of #0.015 each.
The above figure of 7,191,883 Ordinary Shares may be used by shareholders in the
Company as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change in their interest in,
the share capital of the Company under the FSA's Disclosure and Transparency
Rules.
Application has been made for, and the Placing is conditional upon, admission of
the 653,806 shares to trading on AIM.  It is expected that Admission will become
effective and dealings will commence at 8:00 a.m. on 21 November 2007.
For further information, please contact:
Matthew Walls
CEO Epistem Holdings Plc
Tel:  +44 (0)161 606 7258
Thilo Hoffman
Landsbanki Securities (UK) Limited
Tel:  +44 (0)207 426 9000
Mike Wort / Anna Dunphy
MC Bio-Communications Limited
Tel:  +44 (0)207 744 7711
                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
IOEEBLFLDFBXFBB